<DOC>
	<DOCNO>NCT01918306</DOCNO>
	<brief_summary>This phase I/II trial study evaluate tolerability best tolerate dose PI3K inhibitor GDC-0941 give chemotherapy cisplatin . This study also examine well combination GDC-0941 cisplatin work treat patient androgen receptor negative triple negative metastatic breast cancer . Patients randomize receive cisplatin alone cisplatin GDC-0941 phase II portion . Those receive cisplatin alone receive GDC-0941 upon progression disease . Cisplatin chemotherapy show effective treat triple negative breast cancer . Preclinical study show add PI3K inhibitor GDC-0941 cisplatin may effective treatment breast cancer .</brief_summary>
	<brief_title>GDC-0941 Cisplatin Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety tolerability GDC-0941 give combination cisplatin patient androgen receptor-negative ( AR- ) triple negative ( TN ) metastatic breast cancer ( MBC ) : assessment dose limit toxicity ( DLTs ) first 4 week treatment ( cycle 1 ) ; determination maximally tolerate dose ( MTD ) recommend phase II dose GDC-0941 give combination cisplatin . ( Phase IB ) II . To evaluate efficacy , measure overall response rate ( ORR ) , cisplatin + GDC-0941 versus cisplatin alone patient AR- TN MBC . ( Phase II ) SECONDARY OBJECTIVES : I . To determine clinical benefit rate ( CBR ) cisplatin + GDC-0941 patient AR- TN MBC . II . To determine time disease progression ( TTP ) cisplatin + GDC-0941 versus cisplatin alone patient AR- TN MBC . TERTIARY OBJECTIVES : I . To characterize pharmacokinetics GDC-0941 administer combination cisplatin . II . To explore predictor response mechanism resistance base exploratory analysis tumor tissue obtain biopsy . III . To assess prognostic effect phosphatidylinositol-4,5-bisphosphate 3-kinase , catalytic subunit alpha ( PIK3CA ) mutation phosphatase tensin homolog ( PTEN ) loss TTP CBR . OUTLINE : This phase I , dose-deescalation study PI3K inhibitor GDC-0941 follow randomized phase II study . PHASE I : Patients receive cisplatin intravenously ( IV ) 1 hour day 1 , 8 , 15 PI3K inhibitor GDC-0941 orally ( PO ) daily ( QD ) day 2-6 , 9-13 , 16-20 , 23-27 . Courses repeat every 28 day absence disease progression unacceptable toxicity . PHASE II : Patients randomize 1 2 treatment arm . ARM I : Patients receive cisplatin IV 1 hour day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients may crossover Arm II upon disease progression . ARM II : Patients receive cisplatin Arm I PI3K inhibitor GDC-0941 PO QD day 2-6 , 9-13 , 16-20 , 23-27 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Patients must provide informed write consent . Patients must &lt; 18 year age . ECOG performance status 01 . Clinical stage IV invasive mammary carcinoma , ER negative ( defined expression ER &lt; 5 % cell ) , PR negative ( defined expression PR &lt; 5 % cell ) , HER2 negative [ acceptable FDA approve method HER2 analysis include IHC ( 0 , 1+ ) , fluorescence situ hybridization ( FISH ) HER2/CEN17 ratio &lt; 2 , and/or chromogenic situ hybridization ( CISH ) ] HER2/CEN17 ratio &lt; 2 , previously document histological analysis . Androgen receptor negativity , define &lt; 10 % tumor cell nuclei immunoreactivity AR CLIA certify laboratory . See section 5.1 . Measurable disease , define least one lesion accurately measure least one dimension RECIST criterion 1.1 , radiologic scan within 21 day day 1 , cycle 1 . Up one prior chemotherapy regimens metastatic disease . No prior treatment cisplatin metastatic setting . Biopsy metastatic lesion patient reasonably accessible metastatic lesion ( chest wall , skin , subcutaneous tissue , lymph node , skin , breast , bone , lung , liver metastasis ) . If reasonably accessible site available biopsy , patient must agree biopsy . Life expectancy ≥ 6 month opinion investigator Patients must adequate hematologic , hepatic , renal function . All test must obtain less 21 day day 1 study treatment . This include : ANC &gt; /=1500/mm3 Platelet count &gt; /=100,000/mm3 Hemoglobin ≥ 9 g/dL Creatinine &lt; /=1.5X upper limit normal ( ULN ) INR ≤ 2 Total serum bilirubin ≤ 1.5 x ULN ( patient know Gilbert Syndrome , total bilirubin ≤ 3.0 x ULN , direct bilirubin ≤ 1.5 x ULN ) AST ALT ≤ 3 x ULN ( ≤ 5.0 x ULN hepatic metastasis present ) For patient without know Type II diabetes , follow require screening : Fasting blood glucose &lt; /= 135 mg/dL ( 7.49 mmol/L ) glycosylated hemoglobin ( HbA1c ) &lt; 7.0 % International Federation Clinical Chemistry ( IFCC ) &lt; 53 mmol/mol For patient Type II diabetes receive oral antihyperglycemic therapy ( patient receive insulin eligible ) , follow require screening : HbA1c &lt; 8.5 % IFCC &lt; 69.4 mmol/mol Stable regimen oral antihyperglycemic therapy without insulin usage least 3 week prior first study treatment Fasting blood glucose level &lt; /= 160 mg/dL ( 8.88 mmol/L ) hypoglycemia ( BS &lt; 60 ) home monitoring least 1 week prior study entry Patients must able swallow retain oral medication . For patient postmenopausal surgically sterile ( absence ovary and/or uterus ) , agreement remain abstinent use two adequate method contraception , include least one method failure rate &lt; 1 % per year ( e.g. , hormonal implant , combine oral contraceptive , vasectomy/vasectomized partner , tubal ligation ) , treatment period least 30 day last dose GDC0941 6 month last dose cisplatin , whichever longer ; postmenopausal define : Age &gt; /= 60 year Age &lt; /= 60 year amenorrheic 12 month absence chemotherapy , tamoxifen , toremifene , ovarian suppression ; follicle stimulate hormone estradiol postmenopausal range Patients may receive radiation therapy painful bone metastasis area impend bone fracture long radiation therapy complete ≥ 2 week prior day 1 cycle 1 treatment . Patients receive prior radiotherapy must recover toxicity ( ≤ grade 1 ) induce treatment . Baseline radiologic scan must obtain completion radiation . Patients must complete screen assessment outline protocol . Any kind malabsorption syndrome significantly affect gastrointestinal function . Concurrent anticancer therapy ( chemotherapy , radiation therapy , surgery , immunotherapy , hormonal therapy , biologic therapy ) one specify protocol . Patients must discontinue cancer therapy 1 week prior first dose study medication , well recover toxicity ( ≤ grade 1 , except alopecia ) induce previous treatment . Any investigational drug discontinue 2 week prior first dose study medication radiotherapy must complete ≥ 2 week prior initiation study drug ( Cycle 1 , Day 1 ) . Prior use PI3K , Akt inhibitor neoadjuvant , adjuvant , metastatic setting treatment cancer . These include , limited : GDC0941 , GDC0980 , GDC0032 , BEZ235 , BKM120 , LY294002 , PIK75 , TGX221 , XL147 , XL765 , SF1126 , PX866 , D87503 , D106669 , GSK615 , CAL101 . Patients receive PI3K/Akt inhibitor previously &lt; 4 week eligible . Pregnant lactating woman . Insulindependent diabetes . Patients Type II diabetes must meet criterion outline Inclusion Criteria . Uncontrolled intercurrent illness include , limited : Ongoing active infection require parenteral antibiotic Impairment lung function ( COPD &gt; grade 2 , lung condition require oxygen therapy ) current dyspnea rest Symptomatic congestive heart failure ( class III IV New York Heart Association classification heart disease ) Known Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % . Unstable angina pectoris , angioplasty , stenting , myocardial infarction within 6 month Uncontrolled hypertension ( systolic blood pressure &gt; 160 mm Hg diastolic blood pressure &gt; 100 mm Hg , find two consecutive measurement separate 1 2 week period despite adequate medical support ) Clinically significant cardiac arrhythmia ( multifocal premature ventricular contraction , bigeminy , trigeminy , ventricular tachycardia symptomatic require treatment [ National Cancer Institute Common Terminology Criteria Adverse Events , Version 4.0 , grade 3 ] QTcF ≥ 480 msec screen EKG Known history QT/QTc prolongation Torsades de Pointes ( TdP ) ST depression elevation ≥ 1.5 mm 2 lead Diarrhea cause ≥ CTCAE grade 2 Active autoimmune disease control nonsteroidal steroidal ( &lt; 10 mg prednisone per day ) anti inflammatory drug active inflammatory disease , include small large intestine inflammation active Crohn 's disease ulcerative colitis , require immunosuppressive therapy Psychiatric illness/social situation would compromise patient safety limit compliance study requirement include maintenance compliance/pill diary Symptomatic brain metastasis ( patient history brain metastasis must clinically stable least 2 week completion radiation treatment , dose steroid equivalent &lt; 10 mg prednisone daily least one week , stable dose therapeutic anticonvulsant ) Known history chronic liver disease , include cirrhosis , current alcohol abuse , infection hepatitis B virus hepatitis C virus ( active carrier ) , renal failure Known history chronic pancreatitis Conditions affect lymphocyte count , HIV infection immunosuppressive therapy Use prohibit drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Triple Negative Breast Cancer</keyword>
	<keyword>Estrogen receptor negative breast cancer</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Stage IV breast cancer</keyword>
	<keyword>HER2 negative breast cancer</keyword>
</DOC>